iSAM Funds UK Ltd Has $2.41 Million Stock Holdings in Biogen Inc. $BIIB

iSAM Funds UK Ltd boosted its stake in Biogen Inc. (NASDAQ:BIIB) by 279.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,191 shares of the biotechnology company’s stock after purchasing an additional 12,666 shares during the period. iSAM Funds UK Ltd’s holdings in Biogen were worth $2,408,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Empowered Funds LLC increased its holdings in shares of Biogen by 64.9% during the first quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock worth $965,000 after buying an additional 2,777 shares in the last quarter. Focus Partners Wealth boosted its holdings in shares of Biogen by 172.2% during the 1st quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock valued at $1,392,000 after acquiring an additional 6,436 shares in the last quarter. Sivia Capital Partners LLC acquired a new stake in shares of Biogen during the 2nd quarter valued at $216,000. Atria Investments Inc grew its position in Biogen by 14.3% during the 2nd quarter. Atria Investments Inc now owns 1,940 shares of the biotechnology company’s stock worth $244,000 after acquiring an additional 243 shares during the last quarter. Finally, Allworth Financial LP increased its holdings in Biogen by 114.3% in the 2nd quarter. Allworth Financial LP now owns 2,179 shares of the biotechnology company’s stock worth $274,000 after purchasing an additional 1,162 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Price Performance

Biogen stock opened at $181.55 on Friday. The stock’s 50 day moving average is $184.10 and its 200 day moving average is $166.76. Biogen Inc. has a one year low of $110.04 and a one year high of $202.41. The firm has a market cap of $26.64 billion, a P/E ratio of 20.61, a P/E/G ratio of 1.47 and a beta of 0.15. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.68 and a quick ratio of 2.03.

Biogen (NASDAQ:BIIB) last released its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. The business had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The company’s revenue for the quarter was down 7.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, research analysts expect that Biogen Inc. will post 15.83 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have commented on BIIB shares. Piper Sandler increased their target price on Biogen from $157.00 to $177.00 and gave the company a “neutral” rating in a research report on Monday, February 9th. TD Cowen upped their price objective on Biogen from $175.00 to $215.00 and gave the company a “buy” rating in a research note on Monday, February 9th. The Goldman Sachs Group reiterated a “buy” rating on shares of Biogen in a report on Monday, February 9th. Morgan Stanley set a $190.00 target price on shares of Biogen in a research report on Sunday, February 8th. Finally, Barclays assumed coverage on shares of Biogen in a research report on Thursday, February 19th. They issued an “equal weight” rating and a $185.00 price target for the company. Twelve analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $205.04.

Insider Buying and Selling at Biogen

In other news, insider Priya Singhal sold 2,660 shares of the stock in a transaction on Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the sale, the insider directly owned 8,043 shares in the company, valued at $1,607,232.69. This represents a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.18% of the stock is currently owned by company insiders.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.